Acesis BioMed
Acesis BioMed is developing a platform of oral drug candidates targeting metabolic and endocrine disorders, with a primary focus on treating male hypogonadism through its lead candidate ACE-167, a non-steroidal therapy that stimulates testosterone production. This approach addresses the significant health issue of declining testosterone levels, which affect a substantial portion of the male population, particularly those with co-morbidities like type 2 diabetes.
- Biotechnology
Funding
Raised to date
$3.1MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
$1.3M across 1 disclosed round
$1.3M · Seed
Announced Mar 2023
Disclosed cumulative: $1.3M
Reported total $3.1M
Incomplete round history. $1.8M of the $3.1M reported total isn’t matched to a known round.
Founders
Product
Features
- Acesis BioMed is developing a platform of oral drug candidates targeting metabolic and endocrine disorders, with a primary focus on treating male hypogonadism through its lead candidate ACE-167, a non-steroidal therapy that stimulates testosterone production. This approach addresses the significant health issue of declining testosterone levels, which affect a substantial portion of the male population, particularly those with co-morbidities like type 2 diabetes.